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Abstract

Orexin A (33 amino acids) and orexin B (28 amino acids) are two naturally occurring
ligands of the G-protein coupled receptor: orexin receptor 1 (OXiR) and orexin
receptor 2 (OX2R). Based on the expression of OXiR in colon cancer cells,
gallium-68 labelled orexin A (15-33) and orexin B (6-28) were developed as potential
PET imaging agents targeting colon cancer cells. Orexin A (15-33) and orexin B (6-28)
were synthesized by Fmoc solid phase peptide synthesis (SPPS). A bifunctional
chelator 1,4,7,10-tetra azacyclo dodecane- N,N',N”,N ”'-tetraacetic acid (DOTA) was
used to attach gallium-68 to orexin A (15-33) and orexin B (6-28). A linker
aminohexanoic acid (Ahx) was incorporated between the targeting peptide sequence
and 68Ga-DOTA complex to reduce the bulky effect of the imaging label on the
binding affinities. It was determined that the IC50 values of Ga-DOTA-Ahx-orexin A
(15-33) and Ga-DOTA-Ahx-orexin B (6-28) were 629 nM and 168 nM respectively.
In order to evaluate the binding affinities in cells, orexin A (13-33) and orexin B (6-28)
were also labeled with fluorescein isothiocyanate (FITC) allowing for fluorescence
microscopy studies. Besides orexin A and orexin B analogues, a potential orexin
receptor antagonist was developed as a potential imaging agent as well and
preliminary synthetic steps were undertaken. This antagonist was proposed to be
labelled with fluorine-18 to form the compound [l8F](4-fluoro-phenyl)-(4-quinozolin2-yl-[l,4]diazepan-l-yl)-methanone as an imaging agent targeting colon cancer cells.
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ligands of the G-protein coupled receptor: orexin receptor 1 (OXiR) and orexin
receptor 2 (OX2R). Based on the expression of OXiR in colon cancer cells,
gallium-68 labelled orexin A (15-33) and orexin B (6-28) were developed as potential
PET imaging agents targeting colon cancer cells. Orexin A (15-33) and orexin B (6-28)
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chelator 1,4,7,10-tetra azacyclo dodecane- N,N’,N ”,N ”’-tetraacetic acid (DOTA) was
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and 68Ga-DOTA complex to reduce the bulky effect of the imaging label on the
binding affinities. It was determined that the IC50 values of Ga-DOTA-Ahx-orexin A
(15-33) and Ga-DOTA-Ahx-orexin B (6-28) were 629 nM and 168 nM respectively.
In order to evaluate the binding affinities in cells, orexin A (13-33) and orexin B (6-28)
were also labeled with fluorescein isothiocyanate (FITC) allowing for fluorescence
microscopy studies. Besides orexin A and orexin B analogues, a potential orexin
receptor antagonist was developed as a potential imaging agent as well and
preliminary synthetic steps were undertaken. This antagonist was proposed to be
labelled with fluorine-18 to form the compound [18F](4-fluoro-phenyl)-(4-quinozolin2-yl-[l,4]diazepan-l-yl)-methanone as an imaging agent targeting colon cancer cells.
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Chapter 1 Introduction
1.1 M olecular Imaging
Molecular imaging is the combination of molecular and cellular biology and in vivo
imaging. It is a non-invasive way to visualize cellular functions and characterize
biological processes in living organisms.1 Molecular imaging has become very attractive
in recent years, because it has great potential in the diagnosis of disease, such as cancer.
Compared with traditional diagnosis, molecular imaging may detect the disease earlier
and more accurately. Molecular imaging is dependent on an imaging device and an
imaging probe (imaging agent). Once an imaging probe is injected into a body, it
accumulates in the specific cells such as tumor cells, or binds to its target which is
overexpressed in those specific cells compared to surrounding normal cells. The imaging
probe is detected by the corresponding imaging device to create an image of its
distribution in the body, which helps analyze the functioning of organs and tissues.

A molecular imaging probe includes two components: targeting component and imaging
component, as shown in Figure 1.1. Targeting components can be peptides, small
molecules, antibodies, proteins or cells and their responsibility is to identify the target of
interest in the body.2 In order to be visualized in vivo, the targeting entity is labelled by
different imaging components, such as radionuclides, fluorophores or contrast agents.

2

Normally, the linker is used between the targeting and imaging components to reduce the
effect of labelling materials on the interaction of targeting entities and their targets.

1

Target

Large ting

Component

Linker

Imaging
Component

radionuclide, dye.
contrast agent, etc.

peptide, antibody,
small molecule, etc.

Figure 1.1 General design of molecular imaging probes.

There are many imaging modalities, such as radionuclide imaging and optical imaging.
Optical imaging uses fluorescent or luminescent probes emitting visible or near infrared
lights. However, the light emitted from fluorophores can only travel a few millimetres at
most through tissues, so optical imaging is widely used in cells, skins and small animals,
but not in deep tissues. Radionuclide imaging can visualize radionuclide-labelled probes
with a very low concentration, but the resolution of the image is low. Based on different
labelling radionuclides, radionuclide imaging can be divided into single-photon emission
computed tomography (SPECT) imaging and positron emission tomography (PET)
imaging. Figure 1.2 shows an example of the whole-body PET imaging with fluorine-18
labelled fluorodeoxyglucose ( l8F-FDG) as the imaging probe. FDG, an analogue of
glucose, is taken up by the organs or cells with high glucose consumption, such as brain,
kidney and cancer cells.
2

Figure 1.2

(a) Structure of l8F-FDG. (b) The image of the whole-body PET scan using l8F-

FDG. It shows the normal accumulation of the radiotracer in the heart, bladder, kidneys
and brain. Liver metastases of a colorectal tumor are also visible within the abdominal
region of the image.3

1.2 Positron Emission Tomography (PET) Imaging
Positron emission tomography is a non-invasive imaging modality using probes labelled
with positron emitting radioisotopes, such as 68Ga and l8F. PET was originally developed
in the 1960s and PET imaging agents give both qualitative and quantitative measurement
of biological processes. Figure 1.3 shows the basic principle of PET imaging.4 The
neutron-deficient nucleus remains stable through the transmutation of a proton (p) into a
neutron (n), emitting a positron (p4) and an electron neutrino (v). Then the positron
travels a short distance and annihilates with an electron from the surrounding
environment. The positron and electron annihilate, followed by the emission of two
photons of 511 keV 180° apart. The two gamma photons are captured in coincidence by
two detectors on the opposite directions. Based on those detected coincidences, a 3D
image is produced.
3

Figure 1.3. The basic principle of PET technique.

1.3 Gallium-68: A Radionuclide for PET Imaging
In PET/SPECT imaging, imaging entities are labelled by radionuclides. Based on their
decay type, physical half life, availability and ease of labelling, some radionuclides have
preferential characteristics for labelling the imaging agent, including " mTc, l8F, and
68Ga.;>Among those radionuclides, 68Ga may be used to create PET imaging agents. 68Ga
decays by positron emission (89%) and electron capture (11%) with a short physical half
life of 68 minutes, capable of minimizing the radiation exposure to subjects.6 In addition,
68 minutes is also long enough for the radiotracer to reach the target and to get the target
image through a PET scan. The major advantage of using 68Ga as a medical isotope is
that 68Ga can be produced by a 68Ge/68Ga generator system (Figure 1.4) rather than an on
site based cyclotron system, and is more accessible and more cost-effective. As indicated
in Figure 1.4, the parent isotope of 68Ga is 68Ge, which is produced from a gallium target

4

by the (p, 2n) reaction. The half life of 68Ge is 270.8 days, giving a long-lived generator
system.

Figure 1.4 Production and decay of 68Ge and 68Ga.6

In order to attach 68Ga to the targeting entity, a bifunctional chelator is generally used to link them
together, especially in the design of peptide-based imaging probes. Because Ga3+ is a hard
Lewis acid, it normally complexes with hard Lewis bases to form a thermally stable
compound. The ideal chelators should contain oxygen, nitrogen or sulfur donor atoms,
such as carboxylate and phosphonate, but also softer functional groups (Figure 1.5).7

HOOC— \ / ---- s .— COOH
-N
N-

C J
N

HOOC— /

N

N'
x
N— COOH

(a)

HOOC

-COOH

“V

COOH / — COOH

HOOC
N

''— COOH

HOOC
L cooh

(b)

(C)

Figure 1.5 Commonly used chelators, (a) DOTA, (b) NOTA, (c) DTPA.

5

1.4 Fluorine-18: A Radionuclide for PET Imaging
Fluorine-18 decays by 97% through positron emission with a physical half-life of 109.7
minutes. It is a radionuclide that is widely used in molecular imaging by the way of PET
scans. [l8F]Fluoride is usually produced in a cyclotron from 180(p, n)18F nuclear reactions
on 180-enriched water.8,9 This route becomes highly attractive due to its high yield.8 The
synthetic methods of 18F labelled radiotracer include electrophilic fluorination and
nucleophilic fluorination.8 The method most commonly used is nucleophilic fluorination,
which gives a target compound with high specific radioactivity. In nucleophilic
fluorination, nucleophilic addition is very rare, while nucleophilic substitution with
[18F]fluoride is widely used in both aromatic (SuAr) and aliphatic (Sn2) series. The
nucleophilic substitution can be performed directly on a suitable precursor as shown in
Scheme 1.1.10

Scheme 1.1

18F-fluorination and subsequent hydrolysis for the preparation of [18F]FDG

via the method of direct nucleophilic substitution.10

However, the peptides and proteins have many acidic functionalities such as carboxylic
acid, which can also react with [I8F]fluoride.11,12 Besides, the 18F labelling condition is
very basic, which may cause dénaturation of the peptide. Thus, efficient site-specfic 18F
labelling of peptides and proteins has to be carried out by indirect fluorination through
suitable prosthetic groups.13 One of the most suitable prosthetic groups is A-succinimidyl
6

4-[18F]fluoromethyl benzoate ([18F]SFB), which introduces 18F into a peptide via
coupling to the amino group or a lysine residue of the peptide.14 Scheme 1.2 shows the
preparation of [18F]SFB and the [18F]fluorination of a peptide via [18F]SFB.

[18F]SFB

Scheme 1.2

A general procedure for the preparation of 18F-labelled peptides via

[18F]SFB with TSTU as the coupling agent. [I8F]FBA, [18F]fluorobenzoic acid; [l8FJSFB,
iV-succinimidyl 4-[18F](fluoromethyl) benzoate; TSTU, 0-(N-succinimidyl)-N,N,N’,N'tetramethy luronium tetrafluoroborate.1315

1.5 Fluorescence Imaging
Fluorescence imaging is based on detecting the fluorescent emission through cells or
biological tissues, in which a fluorophore is used to label the targeting entity. When the
fluorophore absorbs the light with a specific wavelength, the fluorophore molecule in the
ground electronic state (So) is excited to the vibrational states in the first (Si) or second
(S2) excited electronic states (Figure 1.6). Due to collisions with other molecules, the
excited molecule loses energy and falls to the lowest vibrational level of excited states.
Then the molecule from the lowest excited electronic state returns back to the ground
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electronic state, emitting the energy in the form o f fluorescence.

M e r g p liV

he
Aem

Figure 1.6 Principle of fluorescence spectroscopy.

One of the commonly used fluorophores is fluorescein isothiocyanate (FITC), which is an
amine reactive derivative of fluorescein dyes (Figure 1.7). FITC has a maximum
excitation wavelength of 495 nm and a maximum emission wavelength of 521 nm. In the
design of peptide-based molecular imaging probes, FITC was incorporated to the imaging
entity via the reaction between the isothiocyanate functionality of FITC and the amino
functionality of the peptide-based targeting entity (Scheme 1.3).

Figure 1.7 (a) The structure of fluorescein, (b) The structure of fluorescein
isothiocyanate (FITC).
8

1.6 Peptide-based M olecular Imaging Probes
As a product of genes, biologically active peptides play a significant role in the body via
specific binding activities with their receptors.1617 These receptors are proteins or
protein-coupled receptors, such as G-protein coupled receptors (GPCRs). Many of these
receptors are overexpressed in certain diseases, especially in some tumor cells.18 Through
binding with their receptors, those naturally occurring peptides can activate or inhibit the
corresponding biological processes. Thus, the specific receptor binding of a peptide may
provide a way for cancer targeting via peptide-based molecular imaging. As a targeting
entity, the peptide can be labelled by different imaging components, such as radionuclides
and fluorophores. There are several advantages to use peptides as targeting entities.16
First of all, specific peptides have high binding affinities with their receptors, which is the
prerequisite to screen or monitor certain diseases. Besides, selected peptides are active at
nanomolar concentrations with a low molecular weight, so they can be highly taken up by
the target receptor and cleared from the blood easily. Also, capillary permeability of
peptides is better than that of antibodies, which help them penetrate into the targets
efficiently. Finally, peptides have low toxicity and immunogenicity, reducing the
possibilities of potential adverse effects.

9

One of the representative peptide-based imaging probes in clinical study is 68Ga-[DOTATyr3]-octreotide (68Ga-DOTA-TOC), a somatostatin (SST) analogue, which was designed
to target neuroendocrine tumor cells (Figure 1.8).19 SSTs are a family of cyclopeptides
inhibiting the secretion of insulin, hormone and glucagon.

Somatostatin receptors

(SSTrs) are overexpressed in tumors such as breast cancer and neuroendocrine tumors.

21

Based on the targets SSTrs, some potential SST-based imaging probes have been
developed such as 68Ga-DOTA-TOC. Clinical study of 68Ga-DOTA-TOC has
demonstrated that it is effective for the imaging of neuroendocrine tumors.22

Figure 1.8 Structure of 68Ga-DOTA-TOC.

1.7 Solid Phase Peptide Synthesis
Solid phase peptide synthesis (SPPS) was first developed by Robert Bruce Merrifield in
1963, which earned him the Nobel Prize in 1984.23 SPPS is a method by which the
peptide chain is synthesized on a solid support. The solid support is composed o f small
solid beads, insoluble yet porous. These solid insoluble beads are modified by linkers,
which behave as a reversible linkage between the peptide chain and the solid beads
(Figure 1.9).24 The general principle of SPPS is shown in Figure 1.10.24 The first amino
10

acid is attached to the solid support covalently by its carboxyl group. After deprotection,
the free N-terminal amine is coupled to the next amino acid. The cycle of deprotectionwash-coupling-wash is repeated until the desired amino acid sequence is synthesized.
Finally, the peptide sequence is cleaved from the solid support by trifluoroacetic acid
with water, triisopropylsilane and phenol as scavengers, and all the side-chain protecting
groups are removed as well. There are several advantages of SPPS.24 The intermediates
can be filtered and washed off, saving a lot of time and labour compared to solution
phase synthesis; the coupling reaction can be driven to completion by adding excess
reagents during each cycle; the physical losses can be minimized due to the peptides’
attachment to the solid support. One disadvantage of SPPS is that a lot of by-products
may arise due to incomplete reactions, side reactions or impure reagents.24 These by
products accumulate on the solid support and contaminate the final products, lowering
the overall yield.

Figure 1.9 (a) Structure of Wang resin, acidolysis to peptide acids, (b) Structure of Rink
amide resin, acidolysis to peptide amides.
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Figure 1.10 The general principle of solid phase peptide synthesis.24

1.8 Scope o f this Thesis
As a molecular imaging modality, the clinical applications of PET imaging for oncology
have been established in the past few years. It has a significant role in the diagnosis,
staging, therapy monitoring and assessment of recurrence in cancer.4 The aim of this
thesis is to design orexin peptide analogues and orexin receptor antagonists as potential
PET imaging probes for the diagnosis of disease, such as colon cancer which is the third
most commonly diagnosed cancer in the world.

Orexin receptor 1 (OXiR) and orexin receptor 2 (OX2R) are G-protein coupled receptors

12
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(GPCRs), which were discovered in 1998. ’ As two neuropeptides, orexin A and orexin
B are two endogenous ligands of OXiR and OX2R, regulating food-intake and sleepawake cycle.

In 2004, it was found that OXiR is expressed in colon cancer cells but not

in normal colon cells. Based on the target of OXiR, gallium-68 labelled truncated orexin
A and orexin B were designed as potential peptide based imaging agents targeting colon
cancer cells.

Because of the roles in regulation of food-intake and sleep-awake cycle, orexin receptor
antagonists, a series of bioactive organic molecules, were developed in the past decade by
pharmaceutical companies. Their high binding affinities to orexin receptors leads to the
second research project of designing an orexin receptor antagonist for PET imaging, by
incorporating fluorine-18 into the antagonist molecule.
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Chapter 2 Design of Orexin Peptide Based Imaging
Agents
2.1 Introduction
2.1.1

Discovery of Orexin Peptides and Their Receptors

In 1998, orexin A and orexin B were identified as two neuropeptides expressed in the
hypothalamus area by two independent groups.1 : Orexin A and orexin B are derived from
the same prepro-orexin precursor (Figure 2.1), composed of 131 amino acid residues.2 As
shown in Figure 2.1, orexin A has 33 amino acids with the C-terminus amidated and
orexin B has 28 amino acids with the C-terminus amidated as well.2 Orexin A and orexin
B are two endogenous ligands of two G-protein-coupled receptors (GPCRs), which are
named orexin receptor 1 (OXiR) and orexin receptor 2 (OX2R).2 Orexin A has almost the
same binding affinity for both OXiR and OX2R, while orexin B has a 10-fold higher
affinity for OX2R than for OXiR.2

Figure 2.1 The post-translational cleavage of prepro-orexin. Orexin A starts with Gin ’4,
which is presumably transamidated into an N-terminal pyroglutamyl residue by
transaminase. The last residue of orexin A is Leu66, which is followed by Gly67. Gly67
presumably serves as the -N H 2 donor for the C-terminal amidation of orexin A. Orexin B
starts with Arg70 and ends with Met97, also C-terminally amidated.2
16

2.1.2 Structures of Orexin A and Orexin B
Orexin A has 33 amino acids with two disulfide bonds connecting positions 6 to 12 and 7
to 14. Orexin B has 28 amino acids, with 46% sequence identity with orexin A mainly in
the C-terminal region (Figure 2.2). Orexin A is completely conserved in several
mammalian species (human, rat, mouse, cow, sheep, dog, and pig). However, human
orexin B is slightly different among these mammalian species. For the orexin B in the
dog, pig, sheep and cow, serine at position 2 is substituted by proline, whereas mouse and
rat orexin B contains proline instead of serine at position 2 and asparagine instead of
serine at position 18 (Figure 2.2).3'5

Orexin A (human/rat/mouse/pig/dog/sheep/cow)

EPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2
Orexin B
human

RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2

pig/dog/sheep/cow

RPGPPGLQGRLQRLLQASGNHAAGILTM-NH2

mouse/rat

RPGPPGLQGRLQRLLQANGNHAAGILTM-NH2

Figure 2.2

Theamino acid sequences of orexin A and orexin B in several mammalian

species (human, rat, mouse, pig, dog, cow, sheep).

Three independent research groups have studied the secondary structure of orexin A. In
2003, Mark Miskolzie published that orexin A contains two helices spanning the residues
Asp to Gin and Leu

to Gly . However, based on Hai-Young Kim’s study published
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in 2004, orexin A has two helices, Cysl4-His21 (Helix I) and Asn25-Leu31 (Helix II)
(Figure 2.3a).7 It was also mentioned that the two disulfide bonds make a rigid turn
conformation between the Arg8-Thr" residues. In Tomoyo Takai’s publication in 2006,
the secondary structure of orexin A was defined as Leu -Ala* (helix I), Asn -Thr
(helix II) and Cys6-Gln9 (helix III).8 Similar to orexin A, orexin B has two helices
comprised of the residues Leu7 to Gly19 and Ala2’ to Met28, connected by a flexible loop
(Figure 2.3b).9 All the studies about the secondary structure of orexin A and orexin B
have been summarized in Figure 2.4.

Figure 2.3

(a) The secondary structure of orexin A published by Tomoyo Takai in

2004.8 (b) The secondary structure of orexin B.9
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Figure 2.4 The secondary structures of orexin A and orexin B. (a) orexin A structure by
Miskolzie M. et al.6 (b) orexin A structure by Kim H. Y. et al.7 (c) orexin A structure by
Takai T. et al.8 (d) orexin B structure by Lee J. H. et al.9

2.1.3 Binding Study o f Orexin A and Orexin B
The binding affinity of the peptides orexin A and orexin B at their two receptors was
carried out by John G. Darker in 2001 and Manja Lang in 2004.10,11 The EC50 values of
human orexin A are 0.09 pM at OXiR and 0.06 pM at OXiR, which indicates orexin A
has similar binding affinities at both receptors (Table 2.1). However, orexin B has a
higher binding affinity at OX2R (0.07 pM) than at OXiR (0.78 pM). Through an Nterminal truncation study, it was identified that the shortest orexin A analogue with a
strong agonist effect is orexin A (15-33), while orexin B (6-28) is shortest analogue of
orexin B.10,11 In the design of molecular imaging agents, targeting peptides with low
molecular weights are favoured.1' Small peptides have favourable biodistribution patterns,
19

such as high uptake by the target and rapid clearance from the body.1" Also, small
peptides penetrate into target tissue more efficiently due to better capillary permeability.
Compared with full-length orexin A and orexin B, the analogues orexin A (15-33) and
orexin B (6-28) are better targeting entities for the design of orexin peptide-based
imaging agents.

Table 2.1 The binding affinities of orexin A, orexin B and their analogues."
EC50 ât OXjR

EC50 at OX2R

Selectivity

(pM)

(pM)

OX,R/OX2R

Human Orexin A

0.09 + 0.05

0.06 ± 0.02

1.5

Human Orexin B

0.78 ±0.07

0.07 ± 0.03

11.1

Human Orexin A ( 15-33)

1.79 ±0.46

0.42 ± 0.08

4.3

Human Orexin B (6-28)

0.73 ± 0.04

0.13 ±0.06

5.6

Peptides

The effect of a single amino acid residue on binding activities was investigated by the Lalanine scan.10 " The replacement of a single amino acid by L-alanine led to a great loss
of the activity at both receptors for the amino acids Leu16, Leu19, Leu20, His"6, Gly29, He30,
Leu31, Thr32 and Leu’3 in orexin A (15-33). When Leu16, Gly24, lie'5. Leu26, Thr27 in
orexin B (6-28) were displaced by L-alanine, the EC50 values were above 1000 pM,
incapable of activating orexin receptors. Based on the results from the L-alanine scan
study, it was discovered that most critical amino acids for binding activities are located in
C-terminus, and thus the C-terminal of orexin A (15-33) and orexin B (6-28) are much
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more significant for binding activities than the N-terminal. Therefore, when designing
orexin imaging agents, the imaging label should be attached to the orexin peptides
through the N-terminus rather than C-terminus.

2.1.4 Distribution o f Orexin Receptors
As mentioned in section 2.1.1, orexin A and orexin B bind to two GPCRs, orexin receptor
1 (OXiR) and orexin receptor 2 (OX2R).2 The human OX)R is a protein with 425 amino
acids and seven putative transmembrane helices. The human OX2R is a 444-amino-acid
protein with seven putative transmembrane helices as well. OX2R shares 64% amino acid
identity with OXiR. They were originally identified in the region of brain, but later
studies show that they are also expressed in peripheral tissues, such as kidney, intestine
and pancreas (Table 2.2).2,13’ 17

Studies of the expression of OXiR and OX2R in peripheral tissues established the roles of
orexins in regulating intestinal motility and insulin release, controlling pancreatic
hormone secretion and glucose metabolism.18 In normal pancreas, OXiR-positve cells are
mainly present in the peripheral parts of the islet, while the number and distribution of
OXiR-positive cells are both changed in the diabetic pancreas.19 After the onset of
diabetes, OXiR-positive cells distribute in both peripheral and central regions of islets,
and the number of OXiR-positive cells increases significantly, from 20% to 60% of the
total pancreatic islet cells compared with normal pancreas.19 The differences in the
distribution regions and the number of OXiR-positive cells may lead to the development
of orexin based imaging agents for the analysis of the functioning of pancreas.
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Table 2.2 The expression of orexin receptors in rat tissues.
OX,R

o x 2r

-

-

Pancreas

+

+

+

Liver

_

—

_

Spleen

—

—

—

Heart

—

—

+

+

Lung

—

-

Thyroid

+

-

Rat tissue

OX,R

o x 2r

Rat tissue

Brain

+

+

Stomach

Pituitary

+

+

Adrenal

+

Gonads

+

Kidney

+

Small intestine
Skeletal muscle

+
-

+, detected; -, absent

2.1.5 Expression o f Orexin Receptor 1 in Colon Cancer Cells
In 2004, it was published that OXiR was expressed in colon cancer cells, but it was not
present in normal colonic epithelial cells.20 The expression of OXiR was verified in the
following colon cancer cell lines: Caco2, SW480, LoVo and HT-29. There is one
exception, the HCT 116 colon cancer line, in which no expression of OXiR was observed.
Later research conducted by Voison T. et al. demonstrated that OXiR was expressed in
other colon cancer cell lines as well: HT29-FU, SW620, Colo205, T84, TS174T and
'y

I

SW48 (Figure 2.5).“ The LoVo cell line has the highest expression of OXiR. In Voison’s
research, all the thirty-eight colon tumor specimens tested were immunoreactive for
OXiR. The mean percentage of immunoreactive cells was around 80% (Figure 2.6).
Based on the expression of OXiR in colon cancer cells, it may be feasible to design
orexin based imaging agents targeting colon cancer cells.
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Figure 2.5

Relative OX]R mRNA expression in colon cell lines. LoVo has the highest

expression of OX]R; SW480 has the lowest expression of OXiR; HCT116 doesn’t
j1
express OXiR.

Figure 2.6

A. Paraformaldehyde-fixed sigmoid from a patient with irritable bowel. No

immunoreactive signal was observed. B. Paraformaldehyde-fixed colon tumors in
sigmoid showed immunoreactivity OXiR, indicated by the brown area.“

2.2 Objective
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Colon cancer is the third most commonly diagnosed cancer in the world. Based on the
data from the national organization Colon Cancer Canada, an estimated 22,500 new colon
cancer cases were diagnosed in Canada in 2010 and nearly 9,100 Canadians died from
colon cancer that same year. Colon cancer is 90% treatable if detected early. Early
detection is key to the cure of colon cancer. Molecular imaging may provide a way for
the early detection of colon cancer.

Due to the expression of OXiR in colon cancer cells but not in normal colonic epithelial
cells, orexin A and orexin B have great potential to be designed as molecular imaging
probes targeting colon cancer cells. In order to evaluate the targeting ability in cells,
orexin A and orexin B were labelled by fluorescein isothiocyanate (FITC) to test whether
they were uptaken by colon cancer cells. In order to evaluate the ability to target in vivo,
orexin A and orexin B were labelled by the radionuclide galium-68 to detect colon cancer
cells via PET imaging.

2.3

Results and Discussion

2.3.1 FITC Labelled Orexin A (15-33)
Orexin A (15-33) was made by solid phase peptide synthesis (SPPS) with Rink-amide
resin and Fmoc-protected amino acids starting from the C-terminus of orexin A (15-33).
N-Fmoc was removed by 20% piperidine in dimethylformamide (DMF). Amino acids
were

activated

by

l-[bis(dimethylamino)methylene]-lH-benzotriazolium

hexafluorophosphate 3-oxide (HBTU) in the presence of A//-diisopropylethylamine
(DIPEA). After the synthesis of the peptide sequence, a linker amino hexanoic acid (Ahx)
24

was coupled to the N-terminus of orexin A (15-33) to reduce the effects of the label on
the biological binding activities. Then FITC was attached to the linker by the reaction
between the isothiocyanate functionality of FITC and the amino group of the linker. At
the end, peptide was cleaved off the resin by the cocktail of trifluoroacetic acid (TFA),
water (FFO), triisopropylsilane (TIS) and phenol. Under these conditions, all the
protecting groups were also removed, resulting in the formation of FITC-labelled orexin
A (15-33), that is fluorescein-Ahx-orexin A (15-33) (1). The synthetic procedure of FITC
labelled orexin A (15-33) is shown in Scheme 2.1.

It was found that FITC-labelled orexin A (15-33) was difficult to dissolve in FUO. The
solubility issue might be caused by the following two reasons. First of all, orexin A (15
33) is a long peptide with 19 amino acids and complex structures. More than half of those
19 amino acids are hydrophobic. Second, FITC hardly dissolves in H20 , contributing to
the poor solubility of FITC-labelled orexin A (15-33). In order to improve the solubility
of orexin A (15-33), the short PEG chain [2-[2-amino ethoxy] ethoxy] acetic acid (AEEA)
was used as the linker instead of Ahx. Compared with Ahx linker, AEEA is more
hydrophilic and might improve the water solubility of the peptide. When AEEA was
introduced to FITC-labelled orexin A (15-33), the imaging agent fluorescein-AEEAorexin A (15-33) (2) was made. The solubility of 2 was slightly improved compared to 1.
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Synthetic procedure of FITC labelled orexin A (15-33) with Ahx as the

linker via Fmoc solid phase peptide synthesis. Grey circles represent the solid support,
Rink-amide resin.
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Compounds 1 and 2 were purified by RP-HPLC (reverse phase-high performance liquid
chromatography)

and

characterized

by

ESI-MS

(electrospray

ionization-mass

spectrometry). The results of purity, yield and mass spectrometry are shown in Table 2.3.
The purities of 1 and 2 were both above 90%. Their yields are around 1%.

Table 2.3

Analysis of FITC labelled orexin A (15-33) by RP-HPLC and ESI-MS.

Compound

Calculated m/z

Observed m/z

Purity (%)

Yield (%)

1

840.8 [M+3H]~+

841.5 [M+3H]2+

98

0.8

2

1287.6 [M+Na+H]2+

1288.1 [M+Na+H]2+

94

1.4

2.3.2 FITC Labelled Orexin B (6-28)
By the method of Fmoc solid phase peptide synthesis, the imaging agents fluoresceinAhx-orexin B (6-28) (3) and fluorescein-AEEA-orexin B (6-28) (4) were synthesized
(Figure 2.7). The synthetic procedure of compounds 3 and 4 was the same as that of 1 and

2.

Figure 2.7

Structures of fluorescein-Ahx-orexin B (6-28) (3) and fluorescein-AEEA-

orexin B (6-28) (4). The linker represents Ahx for 3 and AEEA for 4.
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Compounds 3 and 4 were purified by RP-HPLC and characterized by ESI-MS. The
results of purity, yield and mass spectrometry are shown in Table 2.4. The purities of 3
and 4 were both above 90%. Their yields are around 1%.

Table 2.4 Analysis of FITC labelled orexin B (6-28) by RP-HPLC and ESI-MS.
Compound

Calculated m/z

Observed m/z

Purity (%)

Yield (%)

3

1453.7 [M+2H]2+

1454.2 [M+2H]2+

98

1.5

4

1469.7 [M+2H]2+

1470.2 [M+2H]2+

93

1.0

When orexin B (6-28) (5) was analyzed by LC-MS, it always had an impurity, whose
mass was around 16 above the exact mass of 5. The C-terminus of 5 is methionine, which
can undergo alkylation and oxidation. The cocktail used for the cleavage of 5 from the
resin was TFA, TIS, H2O and phenol (88:2:5:5). The scavengers were enough to prevent
the alkylation of methionine. Thus, it was assumed that Met28 was oxidized during the
process of synthesis resulting in the by-product with a mass of 16 above. Also, Met was
at the end of C-terminus, which increased the possibilities for methionine to be oxidized
due to a decreased steric effect.

To verify our assumption, [Ue28]-orexin B (6-28) (6) was prepared where methionine was
displaced by isoleucine. In the mammalian species, the amino acid at position 28 of
orexin B is methionine, while in the orexin B of chickens, the 28th amino acid is
isoleucine (Figure 2.8).3 Because of the similar structures of methionine and isoleucine, it
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was expected that the binding affinity of 5 to the receptors would remain satisfactory
after the methionine was displaced by isoleucine.

Orexin B (6-28)
human

GLQGRLQRLLQASGNHAAGILTM-NH2

chicken

GLQGRLQRLLQASGNHAAGILTI-NH2

Figure 2.8

The amino acid sequences of human orexin B (6-28) and chicken orexin B

(6-28).

As assumed, after methionine was displaced by isoleucine, compound 6 did not have an
impurity with the mass of 16 above, which was supported by the data obtained from LCMS as shown in Figure 2.9 and Table 2.5. Based on the data from ESI-MS, the mass
difference between 5 and [Met(0)28]-orexin B (6-28) (7) was 15.96.

Table 2.5 The ESI-MS data of compounds 6, 7 and 8.
Compound

Peptide

Calculated m/z

Observed m/z

5

Orexin B (6-28)

801.8 [M+3H]i+

804.5 [M+3H]3+

6

[Ile28]-orexin B (6-28)

795.8 [M+3H]3+

798.5 [M+3H]3+

7

[Met(0)28]-orexin B (6-28)

807.1 [M+3H]3+

809.8 [M+3H]3+
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Figure 2.9 (a) HPLC UV chromatogram of crude reaction mixture 5 (RT = 10.44) and 7
(RT = 10.02); (b) Mass spectrum of 7, m/z : 809.8 [M+3H]J+; (c) Mass spectrum of 5,
m/z : 804.5 [M+3H]3+; (d) HPLC UV chromatogram of crude reaction mixture 6 (RT =
10.44); (e) Mass spectrum of 6, m/z : 798.5 [M+3H]3+.
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2.3.3 ^G a Labelled Orexin A (15-33)
FITC labelled orexin A (15-33) was used in the cell study in vitro due to its high
sensitivity and that it is easier and safer to handle fluorophores rather than radionuclides.
However, the use of fluorophores in molecular imaging in vivo has a significant
drawback. When the light propagates through the biological tissues, it can be interfered
with by the tissue autofluorescence and components in the body such as water and
hemoglobin.22 Those effects lead to a shallow penetration depth of fluorescence, only a
few millimeters. Therefore, instead of using FITC labelled imaging agents, 68Ga was used
to label the orexin peptides to form the68Ga labelled imaging agents for animal studies in
PET imaging.

Because 68Ga cannot react with the orexin peptides directly, a chelator has to be used to
connect 68Ga with peptide chains. One of the best-known chelators for 68Ga is 1,4,7,10tetraazacyclododecane-iV,iV’,Ar”,Ar’”-tetraacetic acid (DOTA) (Figure 2.10). Due to the
rigid 12-membered tetraaza macrocycle ring structure of DOTA, its radiometal
compounds are not easy to dissociate kinetically. It is also demonstrated that such
compounds preserve a high thermodynamic stability.23 In addition, DOTA-gallium
complex is a coordinative saturated complex, which greatly reduces the possibility of
ligand exchange or hydrolysis. For 68Ga-DOTA compounds, Ga3+ is coordinated by a
N4O2 donor set to form a cis-pseudooctahedral coordination structure. Besides the two
carboxylic acid groups contributing to the gallium coordination, another carboxylic acid
is conjugated to the amino acid of the peptide (Figure 2.10).24 Due to the advantages of
68Ga labelled DOTA-conjugates, the imaging agent 68Ga-DOTA-orexin A (15-33) (8) was
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designed. The synthetic procedure of DOTA-orexin A (15-33) (9) is shown in Scheme 2.2.
Compound 9 was purified by RP-HPLC and characterized by ESI-MS (Table 2.6).
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C
:Ga' 3 HN-Peptide
^~N ;
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h o 2c
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Figure 2.10 The structures of DOTA (left) and DOTA-peptide labelled by gallium (right).
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20% piperidine in DMF
orexin A 05-33)— 0
Fmoc amino acid,
HBTU, DIPEA
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Fmoc-Ahx
HBTU
DIPEA
DMF

Ahx—

orexin A (15-33)—

0

DOTA(ffiu)3
HBTU
DIPEA
DMF
A (15-33)—

TFA
H20
TIS
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y
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N

N

HOOC-

-COOH

Scheme 2.2 Synthetic procedure for the preparation of 9.
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Table 2.6 Analysis of synthesized DOTA-orexin A (15-33) (9).

Compound

Calculated m/z

Observed m/z

Purity (%)

Yield (%)

9

1270.2 [M+Na+H]*+

1270.7 [M+Na+H]*+

98

5.2

As the element of Period 111 and Group 13, the stable oxidation state of gallium is +3 in
aqueous solution. Ga3+ is only stable in acidic conditions. When the pH is between 3 and
7, insoluble Ga(OH)3 is formed without stabilizing ligands. In basic conditions, Ga(OH)3
re-dissolves into [Ga(OH)4]'. In order to avoid the hydrolysis o f gallium and maximize
the radiolabelling yield, a buffer with a pH range of 3.5-5.0 is normally used during the
radiolabelling process.23 The buffer should have a weak capacity to complex with gallium
and not compete with gallium to form a complex with the chelator. HEPES (4-(2hydroxyethyl)-l-piperazineethanesulfonic acid), acetate, and succinate have been used as
buffering agents, but only acetate is recognized to be suitable for human use.23 Thus, in
the A8Ga radiolabelling process of compound 9, the buffer HOAc/NaOAc (PH-5.0) was
used.

Besides the appropriate buffer, the radiolabelling reaction time has a significant effect on
the radiolabelling yield and imaging process as well. Usually, the time allowed for the
synthesis, purification and utilization of a radionuclide labelled imaging probe is three
half-lives of the radionuclide at most.26 The radiochemical yield of the radiolabelling
synthesis is a compromise between the chemical yield and the radionuclide decay.*7 As a
result, the radiolabelling reaction time should be minimized especially for the short-lived
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radionuclides such as 68Ga and heating provides a way to accelerate the radiolabelling
reaction. Moreover, the radiolabelling kinetics of DOTA-bioconjugates is slow, which
results in a very low radiolabelling yield at room temperature.
temperature is required for the coordination of DOTA and

Thus, elevated reaction
Ga. On the other hand,

peptides are liable to degradation at high temperature, so a temperature-dependent study
was carried out before labelling 9 with 68Ga. The solution of compound 9 was heated at
50°C, 70°C, 80°C, 90°C and 100°C for 20 minutes at each temperature, following by LCMS analysis. Over this temperature range, there was no peptide degradation observed.

The reaction time was studied at 70°C through the reaction between 9 and non
radioactive gallium nitrate in the HOAc / NaOAc buffer. The reaction was followed up by
LC-MS at 5-minute intervals. The labelling reaction was complete within 10 minutes.

Based on the results from the studies of reaction buffer, reaction temperature and reaction
time, the conditions for the radiolabelling of compound 9 with 68Ga were determined. The
radiolabelling reaction was carried out in the NaOAc / HOAc buffer (pH~5) at 70°C for
20 minutes (Scheme 2.3). 68Ga was produced from the 68Ge/68Ga generator and the final
radiolabelled 9 was analyzed by RP-HPLC (Figure 2.11). The radiochemical yield of 8
was 22%.
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Scheme 2.3 Gallium-68 radiolabelling of compound 9.

Figure 2.11

(a) The HPLC radiochromatogram of compound 8. (b) The HPLC UV

chromatogram of the reaction mixture from 68Ga radiolabelling.

2.3.4 68Ga Labelled Orexin B (6-28)
Using the same synthetic procedure as DOTA-orexin A (15-33) (9), DOTA-Ahx-orexin B
(6-28) (10) was synthesized by the method of SPPS. Compound 10 was purified and
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characterized by LC-MS (Figure 2.12 & Table 2.7).

Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-lle-Leu-Thr-Met-NH2

Ira
rg
Gln-Leu-Arg-Gly-Gln-Leu-Gly-Ahx
NH

° t

N

HOOC— /

N

-COOH

N
N'
N---- 7 x— COOH

Figure 2.12 The structure of compound 10.

Table 2.7 Analysis of synthesized DOTA-Ahx-orexin B (6-28) (10).
Compound

Calculated m/z

Observed m/z

Purity (%)

Yield (%)

10

1452.3 [M+2H]Z+

1452.8 [M +2Hf+

95

7.8

The solution of 10 was heated at 70°C, 90°C and 100°C for 20 minutes at each
temperature to observe its degradation property. After 20 minutes of heating, the solution
was analyzed by LC-MS and compound 10 was stable under the above three
temperatures. Since 70°C worked well for the radiolabelling of 9, the labelling reaction
time study of 10 was carried out at 70°C as well. This reaction was followed up by LCMS every 5 minutes over 25 minutes. However, the reaction was not complete after 25
minutes. In order to minimize the reaction time, the temperature was elevated to 90°C and
the reaction was complete within 15 minutes. As a result, the radiolabelling of 10 was
carried out in the HOAc / NaOAc buffer (pH~5) at 90°C for 20 minutes (Scheme 2.4).
68Ga was produced from the 68Ge/6XGa generator and the final 68Ga labelled 10 was
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analyzed by RP-HPLC (Figure 2.13). The radiochemical yield of [68Ga]-DOTA-AhxOrexin B (6-28) (11) was 85%.
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PH 5 HOAC / NaOAc buffer

COOH

90°C

10

20 min

N— Ahx—

orexin B (6-28)— NH2

Scheme 2.4 Gallium-68 radiolabelling of compound 10.

Figure 2.13

(a) The HPLC radiochromatogram of compound 11. (b) The HPLC UV

chromatogram of the reaction mixture from 68Ga radiolabelling.
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As shown in the two chromatograms in Figure 2.13, there was a tiny peak before the
major peak between the retention time of 4 min and 5 min. As mentioned in section 2.3.2,
the Met28 of orexin B (6-28) could be oxidized. The retention time of [Met(0)28]-orexin B
(6-28) (7) was very close to that of orexin B (6-28) (6), only a little bit shorter. Thus,
compound 9 might be oxidized during the radiolabelling process.

2.3.5

Competitive Binding Assay o f Ga-DOTA-Ahx-Orexin A (15-33)

and Ga-DOTA-Ahx-Orexin B (6-28)
The non-radioactive versions of gallium labelled orexin A (15-33) and orexin B (6-28)
were synthesized to determine the half maximal inhibitory concentration (IC50) of orexinbased potential molecular imaging probes (Scheme 2.5). Ga-DOTA-Ahx-orexin A (15-33)
(12) and Ga-DOTA-Ahx-orexin B (6-28) (13) was analyzed by RP-HPLC and
characterized by ESI-MS. The results are shown in Table 2.8.
N— Ahx—

orexin A ( 15-33) — NH2

HOOC-

(N N)
N

Ga(N03)3

N

PH 5 HOAC / NaOAc buffer

-COOH

HOOC-

70°C

9

10min

Scheme 2.5 The gallium labelling of compound 9 to give Ga-DOTA-Ahx-orexin A (1533)(12)
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Table 2.8 Analysis of compounds 12 and 13 by RP-HPLC and ESI-MS.
Compound

Calculated m/z

Observed m/z

Purity (%)

12

1293.2 [M+2H]2+

1293.2 [M+2H]2+

95

13

1508.2 [M+2Na]2+

1508.7 [M+2Na]2+

98

The IC50S of 12 and 13 were determined by the competitive radioligand binding assay
using Chinese hamster ovary (CHO) cells expressing OX|R, through a commercial
Pharmacology company Ricerca Biosciences (Concord, Ohio). Receptor binding was
measured by the competitive binding of [l25I]-orexin A with increasing concentrations of
12 and 13 (10'5 to 10'9 M). Based on the response curves, the concentration of 12 required
to displace 50% of specific radioligand binding (IC50) was 629 nM and the IC50of 13 was
168 nM (Figure 2.14). As expected, their IC50S were lower than those of orexin A and
orexin B, but they were still promising for the design of molecular imaging probes.

Figure 2.14

Competitive binding of Ga-DOTA-Ahx-orexin A (15-33) (12) and Ga-

DOTA-Ahx-orexin B (6-28) (13) versus [l25l]-orexin A on CHO/OXiR cells.
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2.4 Conclusion
This project aims to design orexin analogues as potential imaging probes targeting colon
cancer cells in PET imaging. The orexin A (15-33) and orexin B (6-28) peptide sequences
were labelled with FITC and gallium-68 successfully. The radiochemical yield of [68Ga]DOTA-Ahx-Orexin B (6-28) (8) was low at 70°C in the pH 5 HOAc / NaOAc buffer. To
increase the radiochemical yield, the temperature can be elevated and the pH of the buffer
can be optimized.

The IC50S of Ga-DOTA-Ahx-orexin A (15-33) (12) and Ga-DOTA-Ahx-orexin B (6-28)
(13) were determined as well. Compound 13 has a much higher binding affinity at OXiR
than 12. Based on the binding affinity, compound 13 is the leading candidate for a PET
imaging agent targeting orexin receptors. Besides, orexin B (6-28) is more water soluble
than orexin A (15-33). It is easier to purify orexin B (6-28) than orexin A (15-33).
However, orexin B (6-28) has a drawback as it may be oxidized during the synthetic
process and radiolabelling process. This drawback may be avoided by a further
modification: displacing the methionine at position 28 with another amino acid which
does not significantly affect the binding affinities of orexin B (6-28).

2.5 Experimental
All peptides were synthesized manually or by using an APEX396 peptide synthesizer
obtained from AAPPTec in Louisville with the method of solid phase peptide synthesis
and purified by Waters FractionLynx autopurification RP-HPLC system obtained from
Waters Corporation in Milford. The solvents were purchased from VWR, Fisher

Scientific, or Sigma Aldrich and used without further purification. The Rink-amide resin,
standard Fmoc amino acids, Fmoc-aminohexanoic acid (Ahx), HBTU coupling reagents
were provided by Peptides International in Louisville. DOTA-tris-(tBu)-ester was
obtained from CheMatech in Dijon. The linker [2-[2-amino ethoxy] ethoxy] acetic acid
(AEEA) was synthesized and purified in our laboratory as described in Chapter 3. The
purity of Fmoc-AEEA linker was 97% as analyzed by HPLC.

2.5.1

Synthesis o f FITC Labelled Orexin A Analogue (1 & 2)

Rink amide MBHA resin (0.1 mmol) was swelled in 2 mL dichloromethane (DCM) for 2
minutes, repeated 3 times and then in 2 mL A(A-dimethylformamide (DMF) once. Fmoc
deprotection of Rink amide MBHA resin was performed by agitation in a solution of 20%
piperidine in DMF twice, 5 minutes for the first time and then 15 minutes for the second
time. After the first deprotection, the resin was washed by 2 mL DMF (3 times). After the
second deprotection, the resin was washed by 2 mL DMF (3 times), DCM (3 times) and
DMF (3 times). Amino acid (0.3 mmol) was dissolved in 2 mL DMF and activated by 1[bis(dimethylamino)methylene]-l H-benzotriazolium

hexafluorophosphate

3-oxide

(HBTU) (0.3 mmol) in the presence of AL/V-diisopropylethylamine (DIPEA). The
coupling step was done twice for each amino acid, 45 minutes for the first time and 120
minutes for the second time. The resin was washed by 2 mL DMF (3 times) after each
coupling step. Fmoc-aminohexanoic acid (Ahx) or [2-[2-(Fmoc-amino) ethoxy] ethoxy]
acetic acid (AEEA) was coupled to the N-terminus of peptides using the same
deprotection and coupling conditions described above. Then fluorescein isothiocyanate
FITC (0.4 mmol) dissolved in 2 mL DMF with DIPEA was added into the resin, shaking
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for 4 hours.

The full cleavage of peptides was performed in a solution of trifluoroacetic acid (TFA),
water (H2O), triisopropylsilane (TIS) and phenol (88:5:2:5) for 12 hours. After being
treated in the cleavage cocktail solutions, the resin was removed by filtration and washed
with TFA twice. All the filtrates were combined and cold tert-butyl methyl ether (TBME)
was added into the filtrates. The mixture was cooled down on ice while waiting for the
precipitation of peptides (10 minutes) and then centrifuged at 3000 rpm for 10 minutes at
-10°C. This step was repeated twice, and then the precipitate was dissolved in water,
frozen in dry ice and dried on a lyophilizer yielding solid yellow powders 1 or 2.

The peptides were analyzed and purified by RP-HPLC/ESI-MS. This RP-HPLC system
was equipped with a Waters 600 controller, Waters Prep degasser, and Waters MassLynx
software (version 4.1). The mobile phases were 0.1% TFA in H2O (solvent A) and 0.1%
TFA in CH3CN (solvent B). The linear flow rates of the gradients were 1.5 mL/min and
20 mL/min for analytical and preparative RP-F1PLC. The eluate was monitored by a
Waters 2998 Photodiode array detector. During purification, the fractions were collected
and then lyophilized to become powders and subsequently analyzed by ESI/MS (Waters
Micromass Quattro Micro™ API).

During the peptide synthesis, qualitative amine tests were performed to determine the
completion of coupling reactions.29 The reagents of the qualitative amine test were three
kinds of solutions: 5% ninhydrin in ethanol (w/v), 80% phenol in ethanol (w/v) and 2 mL
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0.001 M potassium cyanide in 98 mL pyridine. After the coupling reaction was done, a
few resin beads were transferred to a small test tube and 3 drops of each of the solutions
above were added into the beads. The solution was mixed well and heated to 120°C for 4
to 6 minutes. A positive result was shown by the colorless solution, which indicated the
absence of resin-bound free amine. If the solution became blue, the coupling reaction was
not complete yet.

2.5.2 Synthesis o f DOTA-Ahx-Orexin B Analogue (3 & 4)
The synthetic procedure of Ahx-orexin A (15-33) and Ahx-orexin B (6-28) was the same
as the peptide synthetic procedure described above. After the coupling of Fmoc-Ahx to
the peptide chains, DOTA-tris (tBu)-ester (0.2 mmol) dissolved in 2 mL DMF with
DIPEA (0.4 mmol) and HBTU (0.2 mmol) was added into the resin, shaking for 24 hours
at room temperature. The procedures of full cleavage, purification and analysis of DOTAAhx-orexin were the same as described above.

2.5.3 Synthesis of Ga-DOTA-Ahx-Orexin A/B Analogues (12 & 13)
Gallium nitrate (10 equiv.) was added into DOTA-Ahx-orexin A (15-33) (9) (2 mg) or
DOTA-Ahx-orexin B (6-28) (10) (2 mg) in 1 mL HOAc / NaOAc buffer (pH~5). The
solution was heated at 70°C for 10 minutes. After the reaction was complete, the resulting
compounds were purified by RP-C18 SPE sep-pak© cartridge. The sep-pak© was rinsed
with 5 mL anhydrous EtOH and then 10 mL FLO. After passing the reaction mixture
through the sep-pak©, 10 mL H2O was used as the eluent to wash out the unreacted
Ga(N03)3 and HOAc / NaOAc buffer. Then 5 mL EtOH was used to wash out the gallium
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labelled orexin A (15-33) or orexin B (6-28). The sep-pak© eluate was evaporated and
lyophilized to yield white powders 12 or 13.

2.5.4 ^G a Radiolabelling of DOTA-Ahx-Orexin A/B Analogues (8 & 11)
DOTA-Ahx-orexin A (15-33) (9) (1 mg) or DOTA-Ahx-orexin B (6-28) (10) (1 mg) was
dissolved in 1 mL NaOAc/ HOAc buffer (pH~5). The solution of 1.61 mCi 68GaCl3 in
diluted HC1 was added to 0.1 mL of the peptide solution. The reaction mixture was
heated at 70°C for compound 9 or 90°C for compound 10 for 20 minutes. Before
purification, the sep-pak© was rinsed with 5 mL anhydrous EtOH and then 10 mL H^O.
After passing the reaction mixture through the sep-pak©, 10 mL H2O was used as the
eluent to wash out the unreacted 68GaCl3 and HOAc / NaOAc buffer. Then 5 mL EtOH
was used to wash out the 68Ga labelled DOTA-Ahx-orexin A (15-33) or DOTA-Ahxorexin B (6-28). The sep-pak eluate was evaporated on a rotary evaporator to give 8 or 11.
They were analyzed by RP-HPLC equipped with a gamma detector.
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Chapter 3 Optimization of AEEA Linker Synthesis
3.1 Introduction
In the design of molecular imaging probes, a linker can be incorporated between the
targeting entity and the imaging moiety to minimize the effects of the imaging moiety on
the biological binding activities of the targeting entity toward its target.1 Figure 3.1 shows
some examples of linkers which have been used in the design of molecular imaging
probes. ' The linker can be a synthesized amphiphilic molecule such as PEG (14), a
natural amino acid such as lysine (15) or an amino acid sequence such as Gly-Gly-Gly
(16). The PEG linker (14) represents a large number of possible molecules, formed by
linking repeating units of ethylene oxide.7 These PEG moieties can be produced in
different configurations (linear or branched structures) and different molecular weights to
optimize the properties of the imaging probes, such as increasing the binding affinity and
enhancing the water solubility.7

17

Figure 3.1

18

19

Structures of linkers: poly ethylene glycol (PEG) (14), lysine (15), Gly-Gly-

Gly sequence (16), 5-amino-3-oxapentyl-succinamic acid (17), aminohexanoic acid (ahx)
(18) and />-aminobenzoic acid (19).
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In 2009, Liu Z. et al. synthesized a 68Ga labelled cyclic RGD dimer ((RGD)2), with 1,4,7triazacyclononanetriacetic acid (NOTA) as the chelator, targeting glioma cells.8 They
found that the use of the PEG4 linker and Gly3 (Gly-Gly-Gly) linker could increase the
binding affinity of NOTA conjugated RGD dimer (Figure 3.2). The IC50 value of NOTA(RDG)2 (20) without a linker was 100 nM.8 However, after the incorporation of the Gly3
linker, the IC50 value of NOTA-(Gly3-RDG)2 (21) was decreased to 66 nM.8 After the
displacement of Gly3 by PEG4, the IC50 value of NOTA-(PEG4-RDG)2 (22) was lowered
to 40 nM.

Figure 3.2

The structures of compounds 20, 21 and 22. The RGD (Arg-Gly-Asp)

sequence strongly binds to the integrin 0^3 receptor, which is overexpressed in several
tumor types including lung carcinoma and breast cancer.1
48

The use of linkers may also reduce the spatial hindrance to improve the labeling yield of
imaging probes.9 Wu Z. et al. demonstrated that the introduction of the PEG3 linker
increased the fluorine-18 radiolabeling yield of tetrameric RGD peptide due to reduced
steric effect (Figure 3.3). The coupling yield between PEG3-(RGD)4 and 18F-SFB (Nsuccinimidyl 4-[l8F]fluorobenzoate) was above 20%, while the yield for the same
coupling reaction between (RGD)4 and l8F-SFB without PEG3 linker was less than 2%.9

Figure 3.3 The structure of l8F labelled PEG-(RGD)4 (23).9

In addition, the incorporation of a linker may alter the pharmacokinetic property of an
imaging probe. Garrison J. C. et al. studied the pharmacokinetic effects of various linkers
using indium-111 radiolabelled bombesin (7-14).4 Bombesin (BBN) is an amphibian
homologue of mammalian gastrin-releasing peptide (GRP).10 It has high binding affinity
to GRP receptor (GRPr), which is overexpressed in several tumors including prostate,
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breast and gastrointestinal tumors.10,11 As a result, various BBN analogues have been
developed as potential imaging probes targeting cancer cells, such as prostate cancer.
Garrison J. C. et al. synthesized six radioconjugates "'in-DOTA-X-BBN (7-14)-NH2
with different linkers (X = 8-aminooctanoic acid (8-AOC), 5-amino-3-oxapentylsuccinamic

acid (5-ADS),

8-amino-3,6-dioxaoctyl-succinamic acid (8-AOS), p-

aminobenzoic acid (AMBA), Gly-AMBA, and Gly-p-aminomethylbenzoic acid (GlyAM2BA)) (Figure 3.4).4 Their study indicated that the imaging probes containing
aromatic linkers exhibited higher in vivo tumor uptake and retention than the ether and
hydrocarbon linkers.4

AMBA

Gly-AMBA

Figure 3.4 Structures o f 11 'in labelled BBN analogues.4

3.2 Objective
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Gly-AM2BA

Orexin A and orexin B had poor solubility in water, especially when they were labelled
with FITC. Compared to the linker aminohexanoic acid, [2-(2-amino-ethoxy)-ethoxy]acetic acid (AEEA) linker is more hydrophilic, so the introduction of an AEEA linker
between the orexin peptide and FITC molecule might improve the water solubility of
FITC labelled orexin based imaging agents. AEEA is a PEG moiety, which is an inert
amphiphilic molecule comprising two units of ethylene oxide. Although the synthesis of
Fmoc-AEEA (24) has been published in a patent, the yield was low in our hands.12 This
project aimed to try different methods to improve the yield of Fmoc-AEEA synthesis.

Figure 3.5 The structure of Fmoc-AEEA (24).

3.3 Results and Discussion
A synthetic procedure of Fmoc-AEEA (24) was provided in the patent literature as
described in Scheme 3.1 and started with commercially available 2-[2-(2-chloro-ethoxy)ethoxy]-ethanol (25).12 After the reaction with sodium azide, triphenylphosphine, water
and Fmoc-Cl, [2-[2-(Fmoc-amino) ethoxy] ethoxyj-ethanol (29) was formed (Scheme
3.1). Then with 2,2,6,6-tetramethylpiperidine-l-oxyl (TEMPO) as the catalyst and
sodium hypochlorite as the oxidant, compound 29 was oxidized into 24 (Scheme 3.2).
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However, in our hands the synthesis of Fmoc-AEEA using the method provided by this
patent gave a very low yield of 26% as compared to the published value of 80%. It was
found that the low yield was due to the inefficient oxidation from compound 29 to 24,
which is shown in Scheme 3.2.

nH

NaN3, DMF

^

' wn _________ ► N3^ v

Cl'

O,

90°C,12h

25

.OH
26
PPh3
24 h
r.t.

H2N

^ 0 ' ^ vO"

.OH

H20

„OH

Ph3P=M/ x - ' L
24h, r.t.

28

27
Fmoc-CI
50°C, 1h
r.t., 24h

Fmoc-HN " ^ ' V ^ " 0 ' ^ 0H
29

Scheme 3.1 Synthetic procedure of [2-[2-(Fmoc-amino) ethoxy] ethoxy] ethanol (29). 12

TEMPO, NaCIO
-------------------------------►
KBr, NaHC03, acetone

Fmoc— N
H
29

-10°C, 1h
r.t., 24h

Scheme 3.2 Synthetic procedure of Fmoc-AEEA (24).12
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24

In order to improve the yield of Fmoc-AEEA synthesis, two additional oxidation methods
were attempted. It has been reported that the addition of sodium chlorite could improve
the yield of TEMPO/NaCIO oxidation.13 When sodium chlorite was used in the FmocAEEA synthesis, the overall yield was improved to 45% (Scheme 3.3). Compared to the
oxidation reaction without sodium chlorite, the yield was increased significantly.

TEMPO, NaCIO, NaCI02
--------------------------------- ►
KBr, NaHC0 3 , acetone

Fmoc-N
H

-10°C, 1h
r.t., 12h

29

Scheme 3.3 The procedure of Fmoc-AEEA synthesis by TEMPO, NaCIO and NaC102.

Another oxidant, Jones reagent, a solution of chromium trioxide in dilute sulphuric acid,
was attempted to oxidize 29 to 10 as well (Scheme 3.4). Jones reagent resulted in a great
increase in the yield of Fmoc-AEEA synthesis, which was 63%, much higher than the
yields of the two methods described previously.

Cr03, H20, H2S04

Fmoc-N
H
29

acetone
0°C, 2h
r.t., 12h

Scheme 3.4 The synthetic procedure of Fmoc-AEEA using Jones oxidation.
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3.4 Conclusion
Among all the three oxidation methods described above, there was an advantage to use
the TEMP0 /NaC10/NaClC>2 method. Compared to the TEMPO/NaCIO method (26%),
the TEMP0 /NaC10/NaC102 method gave a much higher yield (45%). Although its yield
was lower than that given by the method of Jones oxidation (64%), it was easier to work
up and safer. Jones reagent contained chromium which might cause pollution to the
environment, so the waste from this reaction must be disposed of carefully. The
synthesized Fmoc-AEEA was used in the design of orexin based imaging agents.
Fluorescein-AEEA-orexin A (15-33) (2) and fluorescein-AEEA-orexin B (6-28) (4) were
made successfully and the solubility of these two imaging agents was slightly improved.

3.5 Experimental
Sodium hypochlorite was purchased from Queen Bleach Co. Limited in Mississauga.
Sodium azide was obtained from EMD Chemicals in Gibbstown. Fmoc-Cl was provided
by Advanced ChemTech in Louisville. All the other reagents and solvents were
purchased from Sigma-Aldrich and used without further purification. Analytical TLC
was performed on EMD silica gel 60 F254 plates and column chromatography was carried
out by Merck silica gel 60 (230-400 mesh). 'H and 13C NMR data were obtained by
Varian Mercury 400 at 25°C and the chemical shifts were referenced to solvent signals
(CDCI3: 'H 7.27 ppm, ,3C 77.00 ppm) relative to TMS. Mass spectra were obtained from

a Finnigan MAT 8200 mass spectrometer.
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Synthesis of Fmoc-AEEA (24)
Step 1: Synthesis of [2-[2-(Fmoc-amino) ethoxy] ethoxy] ethanol (29)

Fmoc-N
H

29

2-[2-(2-chloro-ethoxy)-ethoxy]-ethanol (25) (3.25 g, 19.4 mmol), sodium azide (1.25 g,
19.4 mmol), and 25 mL dry A^A-dimethylformamide were added into a 100-mL roundbottom flask. The mixture was stirred overnight at 90°C under nitrogen, cooled to room
temperature and diluted with 100 mL of dry tetrahydrofuran. Sodium chloride
precipitated out and was removed by vacuum filtration quickly. Triphenylphosphine
(5.60 g, 20.9 mmol) was added into the filtrate in two batches over 15 minutes under
nitrogen. After stirring for 24 hours, 1.5 equivalent of water (0.6 mL) was added and the
mixture was stirred for another 24 hours. The solvents (THF and DMF) were evaporated
by the rotary evaporator and then an oily liquid was recovered. To this was added 40 mL
water and the precipitated solid was removed by filtration. After washing the solid with 3
x 5 mL water, sodium carbonate (5.50 g, 19.4 mmol) was added to the filtrate and the
solution was kept cool in a water/ice bath. To the cold solution, Fmoc-Cl (5.00 g, 19.4
mmol) dissolved in 25 mL THF was added dropwise over 30 minutes. The reaction was
stirred at 50°C for 1 hour and then at room temperature overnight. After THF was
evaporated, [2-[2-(Fmoc-amino) ethoxy] ethoxy] ethanol (29) was extracted out from the
aqueous layer with ethyl acetate (6 x 50 mL). The extract was dried with MgSCL and then
M gS04 was removed by filtration. The filtrate was evaporated to get a light yellow oil 29.
A small amount of this oil was purified by column chromatography (20% ethyl acetate in
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hexane). 'H NMR (400 MHz, CDC13, 25°C): 5/ppm 7.78-7.75 (m, 2H), 7.62-7.60 (m, 2H),
7.42-7.38 (m, 2H), 7.34-7.29 (m, 2H), 5.53 (bs, 1H), 4.44-4.41 (m, 2H), 4.23 (t, J = 4 Hz,
1H), 3.74-3.50 (m, 10H), 3.41-3.39 (m, 2H). MS-EI: 371.1717 m/z (calc: 371.1733 m/z).

Step 2’: Synthesis of Fmoc-AEEA (24) by TEMPO/NaCIO

Fmoc-N
H

24

Acetone (95 mL) was added to the crude oil 29 (7.20 g, 19.4 mmol) obtained from step 1
and the solution was cooled to -10°C in an iso-propanol/dry ice bath. 5% sodium
bicarbonate solution (95 mL) was added to the cold solution, followed by KBr (0.225 g,
1.9 mmol) and TEMPO (3.40 g, 22 mmol). To this mixture NaOCl solution (30.0 mL,
25.6 mmol, 5.25%) was added dropwise over 10 minutes. After 1 hour, additional NaOCl
(14.3 mL, 12.2 mmol, 5.25%) was added over 5 minutes. The reaction was stirred below
<1

0°C for another 1 hour, then at room temperature overnight. Acetone was evaporated by
’
’
the rotary evaporator, and the light-yellow solution was extracted with ethyl acetate (6 x
50 mL) until the aqueous layer became colorless. The aqueous solution was acidified

J

■
■

with 1M HC1 in a water/ice bath until a precipitate formed (pH~2). The mixture was
stored in the fridge overnight. The resulting precipitate was filtered and dried over
vacuum for 2 days to get the final product as a white powder 24 (1.95 g, overall yield
26.1%). 'H NMR (400 MHz, CDC13, 25°C): 5/ppm 7.77(d, J = 8 Hz, 2H), 7.61 (d, J = 8
Hz, 2H), 7.42-7.39 (m, 2H), 7.34-7.30 (m, 2H), 5.32 (bs, 1H), 4.41 (d, J = 4 Hz, 2H),
4.23 (t, J = 8 Hz, 1H), 4.17 (s, 2H), 3.76-3.42 (m, 8H). 13C NMR (400 MHz, CDC13,
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25°C): 5/ppm 172.53, 156.64, 143.91, 141.29, 127.67, 127.05, 125.08, 119.95, 71.31,
70.31, 69.99, 68.61, 66.78, 47.20, 40.77. MS-EI: 385.1537 m/z (calc: 385.1525 m/z).

Step 2” : Synthesis of Fmoc-AEEA (24) by TEMP0 /NaC10/NaC102

Fmoc-N
H

24

Acetone (30 mL) was added to the crude oil 29 (2.23 g, 6.0 mmol) obtained from step 1
and the solution was cooled to -10°C in an iso-propanol/dry ice bath. 5% sodium
bicarbonate solution (30 mL) was added to the cold solution, followed by KBr (0.07 g,
0.6 mmol), and TEMPO (1.05 g, 6.7 mmol). To this mixture, 0.7 g NaC102 (8.0 mmol)
dissolved in 10 mL water was added dropwise over 10 minutes, and then NaCIO (9.4 mL,
8.0 mmol 5.25%) was added dropwise over 10 minutes. After 1 hour, additional NaC102
solution (5 mL, 6.54%) was added over 5 minutes, followed by additional NaCIO (4.5
mL, 8.0 mmol, 5.25%). The reaction was stirred below 0°C for another 1 hour, then at
room temperature overnight. Acetone was evaporated and the light-yellow solution was
extracted with ethyl acetate ( 6 x 1 5 mL) until the aqueous layer became colorless. The
aqueous solution was acidified with 1M HC1 in a water/ice bath until there was a
precipitate formed (pH~2). The mixture was stored in the fridge overnight. The resulting
precipitate was filtered and dried over vacuum for 2 days to get the product as a white
powder 24 (1.15 g, overall yield 49.8%). The white powder was recrystallized with
ethanol/H20 (3:1) to get the final pure product (1.04 g, overall yield 45.2%).
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Step 2”’: Synthesis of Fmoc-AEEA (24) by Jones oxidation

Fmoc-N
H

24

Acetone (30 mL) was added to the crude oil 29 (2.23 g, 6.0 mmol) obtained from step 1
and the solution was cooled to 0°C in a water/ice bath. Fresh Jones reagent (prepared by
dissolving 1.19 g O O 3 in 16 mL water and then adding 2.2 mL H2SO4) was added to the
mixture, which was stirred at 0°C for 2 hours and then at room temperature overnight.
Iso-propanol was used to quench the reaction. Acetone and iso-propanol were evaporated
to obtain a green-yellow oil. The crude product was purified by column chromatography
(2% methanol in chloroform, 1% acetic acid). After purification, 1.45 g 24 was obtained
and the overall yield was 62.8%.

References
(1)

Lee, S.; Xie, J.; Chen, X. Y. Chemical Reviews 2010,110, 3087.

(2)

Brillouet, S.; Dorbes, S.; Courbon, F.; Picard, C.; Delord, J. P.; Benoist, E.

et al. Bioorganic & Medicinal Chemistry 2010,18, 5400.
(3)

Azad, B. B.; Rota, V. A.; Breadner, D.; Dhanvantari, S.; Luyt, L. G.

Bioorganic & Medicinal Chemistry 2010,18, 1265.
(4)

Garrison, J. C.; Rold, T. L.; Sieckman, G. L.; Naz, F.; Sublett, S. V.;

Figueroa, S. D. et al. Bioconjugate Chemistry 2008, 19, 1803.
(5)

Parry, J. J.; Kelly, T. S.; Andrews, R.; Rogers, R. E. Bioconjugate

Chemistry 2007, 18, 1110.
58

(6)

Dijkgraaf, I.; Liu, S.; Kruijtzer, J. A. W.; Soede, A. C.; Oyen W. J. G.;

Liskamp R. M. J. et al. Nuclear Medicine and Biology 2007, 34, 29.
(7)

Harris, J. M.; Martin, N. E.; Modi, M. Clinical Pharmacokinetics 2001, 40,

(8)

Liu, Z.; Niu, G.; Shi, J.; Liu, S.; Wang, F.; Liu, S. et al. European Journal

539.

o f Nuclear Medicine & Molecular Imaging 2009, 36, 947.
(9)

Scott, W.; Anjali, S.; Mond, J. Antimicrobial Agents and Chemotherapy

2003, 47, 554.
(10)

Smith, C. J.; Volkert, W. A.; Hoffman, T. J. Journal o f Nuclear Medicine

2005, 32, 733.
(11)

Reubi, J. C. Endocrine Reviews 2003, 24, 389.

(12)

Aldrich, J. V.; Kumar, V. U.S. Patent, US20030134989A1, July 17, 2003.

(13)

Zhao, M. M.; Li, J.; Mano, E.; Song, Z. J.; Tschaen, D. M. Organic

Syntheses 2005, 81, 195.

59

Chapter 4 Design of Orexin Receptor Antagonists as
Imaging Agents
4.1 Introduction
4.1.1 Biological Functions of Orexin Systems
Orexin peptides and their receptors are expressed in the lateral hypothalamus and
adjacent areas, a region regulating feeding behavior and energy homeostasis.1'4 It is the
reason that orexin was named after “orexis”, which means appetite in Greek. In 1998,
Sakurai et al. demonstrated that orexin A and orexin B can stimulate food intake in a
dose-dependent way.1 They also found that the production and release of orexin peptides
were affected by the nutritional state of animals. Within 48h fasting, hypothalamic
prepro-orexin mRNA was in a 2.4-fold up-regulation compared with the fed control
animals. Further evidence indicated that the increase of food consumption resulted from
the delay of the onset of a normal satiety sequence via the activation of orexin receptors
by orexin receptor agonists (orexin A and orexin B), while an orexin receptor antagonist
inhibited food consumption and accelerated the onset of a normal satiety sequence.5

Further research found that orexin deficiency contributes to narcolepsy in humans and
animals, which indicates that orexin plays a significant role in regulation of the sleepwake cycle.6"11 The study discovered that a long, consolidated awake period was
maintained due to the activation of wake-active neurons in the hypothalamus and brain
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stem by orexin.6 It was also reported that the orexin A level in the cerebrospinal fluid was
decreased in approximately 90% of patients with narcolepsy, especially those with
narcolepsy-cataplexy.12 As a result, the 2nd edition of the international classification of
sleep disorders introduced a low cerebrospinal fluid level of orexin A as one of the
diagnostic criteria for narcolepsy-cataplexy.13

4.1.2 Development of Orexin Receptor Antagonist
Since orexin participates in the regulation of food-intake and sleep-wakefulness, many
orexin receptor antagonists have been developed as potential drugs for the treatment of
insomnia and obesity. Based on their binding affinities to orexin receptors, the orexin
receptor antagonists can be divided into two groups: selective orexin receptor antagonist
(SORA) and dual orexin receptor antagonist (DORA). Many of these orexin receptor
antagonists have very low IC50 values, even below 1 nM, much lower than those of the
orexin receptor agonists orexin A and orexin B (Table 4.1 & 4.2).

Table 4.1 The IC50 values of orexin receptor agonists (orexin A and orexin B).14
Agonist

IC50 at OXiR (nM)

IC50 at OX2R (nM)

Orexin A

20

250

Orexin B

20

20

6 1

Table 4.2 The IC50 values of some orexin receptor antagonists.14' 16

ill

The first published orexin receptor antagonist is SB-334867-A (32), which binds to

i|
«1

if

OXiR selectively (Figure 4.1).17 It was demonstrated that 32 could reduce the food intake
and body weight and has a potential clinical application in the treatment of obesity.18 To
date, there are three dual orexin receptor antagonists studied in clinical trials: Almorexant
(33), SB-649869 (34) and MK-4305 (35) (Figure 4.1).19 Compound 33 was developed
based on the tetrahydroisoquinoline motif by Actelion Pharmaceuticals.

It has been

proven that 33 can reduce wakefulness in rats, dogs, and humans without cataplexy.21 It
also improved the sleep initiation and sleep maintenance of insomnia patients without
significant next-day effects on motor function in a Phase II study.20 However, the Phase
III study was abandoned because of undesirable side effects. SB-649869 (34), a
derivative of A-acyl piperidine, was developed by SmithKline Beecham.15 Although it
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showed positive results in sleep efficacy, its development was delayed due to preclinical
toxicology findings.19 In 2008, Merck claimed substituted diazepane derivatives as orexin
receptor antagonists, one of which was compound 35. The preliminary Phase I result of
35 showed decreased latency to persistent sleep and wake after sleep onset in healthy
volunteers.19,22

Figure 4.1 The structures of SORA SB-334867 (32) and DORAs Almorexant (33), SB649869 (34) and MK-4305 (35).19

4.1.3 Substituted Diazepane Orexin Receptor Antagonists

In 2009, Merck & Co. Pharmaceuticals published a series of orexin receptor antagonists
based on the substituted diazepane motif. Many of those antagonists have an IC50 value
below 100 nM. Compound 36 is one of those antagonists with a rather low IC50 value
(OX,R IC50 = 29 nM, OX2R IC50 = 27 nM) (Figure 4.2).23

As shown in Figure 4.2, compound 36 adopts a twist-boat ring conformation with an
intramolecular 7t-stacking interaction. It was concluded that the twist-boat ring and lowenergy conformation of A, A-disubstituted-1,4-diazepane orexin receptor antagonists
resulted in a reduced conformational entropy, in order to resemble the conformation of
the required binding orientation.24 To investigate the role of 7c-stacking interaction in the
biological binding activity, compound 37 (cyclohexyl amide instead of benzoic amide)
was synthesized (Table 4.3).24 Without the intramolecular 7t-stacking interaction in 37,
the binding affinity was decreased. The compounds 38 (2-naphthyl analog) and 39
(tertiary amine instead of amide carbonyl) were synthesized to study the binding affinity
as well.24 Through the comparison of binding affinities, it was discovered that the
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quinazoline ring was slightly better than the naphthalene ring and the amide carbonyl was
much better than a tertiary amine.

Table 4.3

The binding affinities o f A(./V-disubstituted-l,4-diazepane orexin receptor

antagonists.24
Compound

36

Structure
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4.1.4 Fluorine-18 Labelled Imaging Agents

In the past 20 years, many fluorine-18 labelled radiopharmaceuticals have been
introduced for human studies, such as 2-deoxy-2-[l8F]fluoro-D-glucose ([l8F]FDG) (40),
which can be utilized as an imaging probe for the diagnosis of cancer.25 Fluorine has a
small atomic radius and forms a strong carbon-fluorine bond, which is the strongest
covalent bond in organic chemistry.26 Due to the small steric size of fluorine, the
molecular size of imaging agents labelled by fluorine-18 does not change significantly,
which might minimize the effects of imaging labels on the biological binding affinities.
Substitution with fluorine can also change the physiochemical and biological properties
of the organic compound significantly and usefully.25 Because the carbon-fluorine bond
is more hydrophobic than the carbon-hydrogen bond, the fluorine addition to biologically
active organic compounds may increase the lipophilicity resulting in an increased cell
membrane penetration.27 Also, the stability of the carbon-fluorine bond may slow down
the metabolism of radiopharmaceuticals, giving a longer time for imaging.

One of the popular fluorine radiotracers is [l8F]FDG (40), which was developed to study
glucose metabolism in the human brain in 1976.25 Later research demonstrated that there
was a high uptake of 40 in the rapidly growing tumors resulting from increased tumor
glycolysis.28,29 To date, many hospitals have used 40 for clinical diagnosis via molecular
imaging in heart disease and in oncology.25 Figure 4.3 shows the image of a [,8F]FDG
PET scan of a 78-year-old woman with colorectal cancer.30 The detection of tumors by a
[l8F]FDG PET scan in many instances is more accurate than the CT scan. Among the 38
patients with colorectal cancer studied by Kantorova Iva in 2003, 95% of primary tumors
were detected by [l8F]FDG PET, while CT only detected 49% of primary tumors.30
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Figure 4.3

[18F]FDG PET scan of a 78-year-old woman with primary rectal carcinoma

(solid arrows) and histologically proven metastasis in lymph nodes (dashed arrows).30

4.2 Objective
It has been established that PET imaging has a significant role in evaluating and staging
recurrent colorectal cancer in patients with 40 as the imaging probe.31 Although
[18F]FDG imaging is quite sensitive in the detection of tumors, the high FDG uptake is
not only specific for tumors.32 Inflammatory processes may also cause an increased
uptake of FDG, resulting in false-positive results, which have been reported in
tuberculosis, presacral abscesses and fungal infections.31 The non-specificity of [l8F]FDG
imaging in the detection of colorectal tumors requires the development of new imaging
probes.
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As described in Chapter 2, OX|R is expressed in colon cancer cells but not in normal
colonic epithelial cells, which led to the idea of designing [18F]fluorinated orexin receptor
antagonists as potential imaging probes targeting colon cancer cells.33 Many orexin
receptor antagonists have been developed in the past ten years and many of them have
high binding affinities to OXiR. After evaluating all of them, the substituted diazepane
orexin receptor antagonists attracted our attention. Those antagonists have low IC50
values and great potential to be labelled by fluorine-18 based on the techniques and the
accessibility of equipment in our laboratory.

As a result, we designed [l8F](4-fluoro-phenyl)-(4-quinozolin-2-yl-[l,4]diazepan-l-yl)methanone (41) as a potential imaging agent (Figure 4.4). Compound 41 has a similar
structure to another orexin receptor antagonist 42 (IC50 < 100 nM). Compounds 42 and
36 are both substituted diazepane orexin receptor antagonists developed by Merck & Co.
Pharmaceuticals, as previously described in section 4.1.3. As shown in Figure 4.4,
compound 41 reserves the significant parts of this class of orexin receptor antagonists for
binding activities, such as amide carbonyl and the aromatic rings. It is proposed that
compound 41 may have a similar binding affinity to that of 36 and 42.

Unlike the radionuclide gallium-68, fluorine-18 does not require a chelator when
attaching it to the targeting entity. It can be incorporated into 41 directly through
nucleophilic fluorination (Figure 4.5). Without the bulky chelator, fluorine-18 may have

less of a negative effect on the binding activity as compared to the effect of a

¿o

Ga-

chelator complex.

Figure 4.4 The structures of compounds 36, 41 and 42. Compounds 36 and 42 belong to
the same class of substituted diazepane orexin receptor antagonists.

Figure 4.5 Design of orexin receptor antagonist as an imaging agent.

4.3 Results and Discussion
The potential imaging agent 41 could be made by the coupling reaction between 2[l,4]diazepan-l-yl-quinazoline (46) and [18F]fluorobenzoic acid (18). Since compound 41
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was designed based on the modification of 42, the synthesis of 41 was similar to that
reported for 42. The general synthetic procedure is provided in Scheme 4.1.34
[l8F]fluorobenzoic acid (47) could be synthesized from a (4-ethoxycarbonyl-phenyl)trimethyl-ammonium precursor (48) by nucleophilic aromatic substitution and be
connected to the target molecule through activation of the carboxyl functionality (Scheme
4.2).35

Scheme 4.1 General synthetic procedure of 41.34

Scheme 4.2 The synthesis of compound 47.35
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One of the critical steps for making 41 was to make 2-chloro-quinazoline (44). The first
approach attempted to make 44 is shown in Scheme 4.3 and follows a method reported in
a patent.36

KNCO
HOAc
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44

Scheme 4.3 The synthetic route of 2-chloro-quinazoline (44).36

As shown in Scheme 4.3, the first step was reducing 2-nitro-benzaldehyde (49) to 2amino-benzaldehyde (50). The reduction of the nitro group was attempted by a catalytic
hydrogenation reaction with 5% and 10% Pd/C as catalyst respectively. However,
multiple products were formed after hydrogenation. One by-product was 2-amino-benzyl
alcohol (52), which was characterized by NMR and Mass spectrometry (Figure 4.6). The
two hydrogen atoms of the amino group had different chemical shifts, which might be
resulted from the hydrogen bonding between -OH and -N H 2. Among the by-products,
another two were separated as a mixture. One of them was 50 based on the data from the
'H NMR spectrum (Figure 4.7). To avoid the over-reduction of 49, the aldehyde group
was protected by ethylene glycol to form 2-(2-nitrophenyl)-l,3-dioxolane (53) with a
yield of 80% (Scheme 4.4). However, there were still multiple products formed when 53
was subjected to catalytic hydrogenation.
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co

r

— 0.08

r

Figure 4.6 The 'H NMR spectrum of a by-product 2-amino-benzyl alcohol (52).

ethylene glycol
p-toluenesulfonic acid
toluene
120°C,24 h

Scheme 4.4 The synthetic procedure of compound 53.
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Figure 4.7 The 'H NMR spectrum of the mixture: 50 and a by-product.
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Since the first approach of making 44 did not work well, a second approach was
attempted, as published in a Merck & Co. Pharmaceuticals patent (Scheme 4.5).34 In
order to avoid the over-reduction of compound 49, the aldehyde functionality was
protected by n-butanol before the catalytic hydrogenation reaction.

1.triphosgene
2. NH3
3. HCI
V

Scheme 4.5 The synthetic procedure for synthesizing 2-chloro-quinazoline (44). 34

Compound 49 was reacted with n-butanol using a Dean-Stark apparatus for 48 hours,
with compound 54 being obtained with a yield of 95%. However, when compound 54
was reduced by hydrogen with Pd/C, multiple products were formed again. One of those
products was separated, which was 2-amino-toluene (56) based on *H NMR data (Figure
4.8). Also, there was a signal corresponding to an aldehyde functionality observed in the
'H NMR spectrum of the crude products. Therefore, the protecting group appears to have
been removed and was not stable under Pd/C hydrogenation conditions.
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Figure 4.8 The ‘H NMR spectrum of by-product 2-amino-toluene (56).

To avoid the deprotection of the aldehyde functionality, a mild reducing agent
hydrazine/Raney nickel was attempted to reduce the nitro group to an amino group
(Scheme 4.6). Unexpectedly, there were three products formed and they had similar
polarity. One product was the desired compound 55 with a yield of 20%. As shown in the
'H NMR spectrum of 55, the amino group had two signals (Figure 4.9). One hydrogen
atom of the amino group might interact with the oxygen atom of the dibutoxymethyl
group by hydrogen bonding to form a six-member ring.
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Scheme 4.6

The synthetic procedure for reduction of compound 54 with Raney nickel

and hydrazine.

Figure 4.9 The 'fi NMR spectrum of 2-amino-dibutoxymethyl-benzene (55).
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4.4 Conclusion
To

make

the

potential

imaging

agent

[l8F](4-fIuoro-phenyl)-(4-quinozolin-2-yl-

[l,4]diazepan-l-yl)-methanone (41), the critical step was to synthesize 2-chloroquinazoline (44). However, the synthesis of 44 was hindered by the non-selective
reduction of 2-nitro-benzaldehyde (49) or l-(dimethoxymethyl)-2-nitrobenzene (54).
Although the reduction reactions were carried out using different reducing agents and
reaction conditions, it did not proceed well. Future work will require an improvement in
the selectivity of reduction reactions. Or it may be attempted to design a different orexin
receptor antagonist and label it with fluorine-18 to form a potential imaging agent.

4.5 Experimental
All reagents and solvents were purchased from Sigma-Aldrich, Alfa Aesar, or VWR.
They were used without further purification unless noted. Analytical TLC was performed
on EMD silica gel 60 F254 plates and column chromatography was carried out by Merck
silica gel 60 (230-400 mesh). 'H and l3C NMR data were obtained by Varian Mercury
400 at 25°C and the chemical shifts were referenced to solvent signals (CDCI3: 'H 7.27
ppm, l3C 77.00 ppm) relative to TMS. Mass spectra were obtained from a Finnigan MAT
8200 mass spectrometer.

4.5.1

Synthesis of 2-Amino-benzaldehyde (50)
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50

0.151 g 2-nitro-benzaldehyde (49) (1.0 mmol) was dissolved in 2 mL DCM and 2 mL
MeOH, followed by adding 15.1 mg 10% Pd-C (10% wt). The mixture was stirred for 4
hours under hydrogen at room temperature. Pd-C was filtered off and the filtrate was
collected. The filtrate was concentrated by evaporating off the solvents DCM and MeOH
by the rotary evaporator to get a light yellow oil. The crude product was purified by
column chromatography (10% EtOAc in hexane, 1% triethylamine). The yield of the by
product 52 is 15.5%. Data for the by-product 2-amino-benzyl alcohol (22): 'H NMR (400
HMz, CDC13, 25°C) 8/ppm 7.17-7.13 (m, 1H), 7.10-7.07 (m, 1H), 6.75-6.71 (m, 2H),
4.69 (s, 2H), 4.19 (bs, 1H), 1.61 (bs, 1H); MS-EI: 123.0685 m/z (calc: 123.0684m/z).
Data for 2-amino-benzaldehyde (50): 'H NMR (400 MHz, CDCI3, 25°C) 8/ppm 9.88 (s,
1H), 7.49 (dd, J = 7.8, 1.6 Hz, 1H), 7.32 (ddd, J= 8.3, 6.9, 1.6 Hz, 1H), 6.76 (m, 1H), 6.66
(d, J = 8.2 Hz, 1H), 6.12 (bs, 1H).

4.5.2 Synthesis of 2-(2-Nitro-phenyI)-[l,3]dioxolane (53)

53
A solution of 49 (0.15 g, 1.0 mmol), /7-toluenesulfonic acid monohydrate (0.02 g, 0.1
mmol) and ethylene glycol (0.19 g, 3.0 mmol) was refluxed in toluene (10 mL) with a
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Dean-Stark apparatus for 24 hours. The reaction was cooled to room temperature and
then the solvent was evaporated off by the rotary evaporator. The crude was purified by
column chromatography (10% EtOAc in hexane) to obtain 0.16 g of 2-(2-nitro-phenyl)[l,3]dioxolane (53) as a light yellow oil. The yield was 82.1%. Data for 53: ’H NMR
(400 HMz, CDC13, 25°C) 5/ppm 7.86 (dd, J = 8, 1 Hz, 1H), 7.77 (dd, J = 7.8, 1.2 Hz, 1H),
7.61-7.57 (m, 1H), 7.49-7.45 (m, 1H), 6.45 (s, 1H), 4.04-3.96 (m, 4H). 13C NMR (400
HMz, CDCI3, 25°C) 5/ppm 148.60, 132.97, 132.70, 129.47, 127.42, 124.16, 99.33, 65.10.
MS-EI ([M-H]+): 194.0451 m/z (calc: 194.0454 m/z).

4.5.3 Synthesis of l-(Dimethoxymethyl)-2-nitrobenzene (54)

A solution of 49 (1.51 g, 10 mmol), /?-toluenesulfonic acid monohydrate (0.20 g, 0.1
mmol) and ethylene glycol (2.53 g, 40 mmol) was refluxed in toluene (40 mL) with a
Dean-Stark apparatus for 48 hours. The reaction was cooled to room temperature and
then the solvent was evaporated off by the rotary evaporator. The crude material was
purified by column chromatography (10% EtOAc in hexane) to obtain 2.68 g 54 as a light
yellow oil. The yield was 95.4%. Data for 54: 'H NMR (400 HMz, CDC13, 25°C) 5/ppm
7.83-7.79 (m, 2H), 761-7.57 (m, 1H), 7.47-7.43 (m, 1H), 6.03 (s, 1H), 3.66-3.60 (m, 2H),
3.54-3.49 (m, 2H), 1.63-1.55 (m, 4H), 1.43-1.34 (m, 4H), 0.91 (t, J = 8 Hz, 1H). 13C
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NMR (400 HMz, CDC13, 25°C) 5/ppm 148.94, 133.65, 132.34, 129.04, 127.99, 124.05,
98.34, 67.48, 31.69, 19.28, 13.79. MS-EI ([M-C4H90 ] +): 208.4 m/z (calc: 208.1 m/z).

4.5.4 Synthesis of 2-Dibutoxymethyl-phenylamine (55)

55

To a solution of 54 (0.84 g, 3.0 mmol) in EtOH (10 mL) and DCE (10 mL) was added
0.15 mL Raney nickel slurry. Then 0.6 mL hydrazine was added dropwise slowly. The
mixture was stirred at room temperature for 30 minutes. Raney nickel was filtered off and
the filtrate was concentrated by evaporating the solvents via the rotary evaporator. The
crude was purified by column chromatography (5% EtOAc in hexane, 1% triethylamine)
to obtain 0.15 g 55 with a yield of 19.9%. Data for 2-dibutoxymethyl-phenylamine 55: 'H
NMR (400 HMz, CDC13, 25°C) 5/ppm 7.89 (s, 1H), 7.36-7.30 (m, 3H), 6.93-6.90 (m, 1H),
6.00 (bs, 1H), 5.36 (s, 1H), 3.57-3.52 (m, 2H), 3.48-3.43 (m, 2H), 1.63-1.54 (m, 4H),
1.44-1.35 (m, 4H), 0.92 (t, J = 8 Hz, 6H). MS-EI ([M]+): 251.1877 m/z (calc: 251.1885
m/z).
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Chapter 5 Conclusion and Outlook
According to World Health Organization statistics, cancer is still the leading cause of
death in the world and 7.6 million people (around 13% of all deaths) died of cancer in
2008.' However, the cancer mortality rate is dropping by about one percent annually and
the five-year survival rate is increasing, which reflects an improvement in the early
diagnosis and effective treatment of cancer.2 This improvement is partially a result of the
application of molecular imaging techniques in cancer diagnostics. Molecular imaging
provides biological information in a human body at the molecular and cellular level,
noninvasively. Through molecular imaging techniques, cancer can be detected in its early
stage before abnormalities can be identified with other diagnostic tests.2 The potential
significance of molecular imaging in cancer diagnosis leads to the work presented in this
thesis, in the design of orexin receptor agonists and antagonists as potential imaging
probes targeting colon cancer cells.

The first research project focused on designing orexin agonists orexin A (33 amino acids)
and orexin B (28 amino acids) as potential imaging agents targeting colon cancer cells, in
which orexin receptor 1 (OXiR) is expressed. Because of favourable biodistribution
patterns of small peptides, the analogues of orexin A and orexin B, orexin A (15-33) and
orexin B (6-28), were developed as potential imaging agents. The N-terminal residues of
orexin peptides are much less significant for biological binding affinities than the Cterminal residues, allowing for attachment of imaging labels to orexin peptides through
the N-terminal residues.
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First of all, orexin A (15-33) and orexin B (6-28) were labelled with fluorescein
isothiocyanate (FITC) for a preliminary cell study in vitro. A linker amino hexanoic acid
(Ahx) was used between the orexin peptide and the imaging label FITC to reduce the
bulky effects of the imaging label on binding affinities. Due to the poor solubility of
FITC-Ahx-orexin A (15-33) (1) and FITC-Ahx-orexin B (6-28) (3), an AEEA linker was
used instead of Ahx, and the solubility of FITC-AEEA-orexin A (15-33) (2) and FITCAEEA-orexin B (6-28) (4) was slightly improved.

A shallow penetration depth limits the use of FITC as an imaging label for animal studies
in vivo, which leads to the design of gallium-68 radiolabelled orexin peptides. Gallium-68
cannot be introduced into orexin peptides directly. Therefore a bifunctional chelator
DOTA was conjugated to orexin peptides, and then coordinated with gallium-68 during
the radiolabelling process. Orexin A (15-33) and orexin B (6-28) were successfully
radiolabelled with gallium-68 via the 68Ge/68Ga generator system to get two imaging
agents 68Ga-DOTA-Ahx-orexin A (15-33) (8) and 68Ga-DOTA-Ahx-orexin B (6-28) (11),
which may be used for PET imaging. The nonradioactive Ga-DOTA-Ahx-orexin A (15
33) (12) and Ga-DOTA-Ahx-orexin B (6-28) (13) were synthesized as well to study their
binding affinities to OXiR. Their IC50 values were 629 nM and 168 nM respectively.

The second research project focused on synthesizing a potential orexin receptor
antagonist 41 and radiolabelling it with fluorine-18 to get an imaging probe targeting
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colon cancer cells. The synthesis of 41 was not completed. Future work may improve the
selectivity of the reduction reaction which hindered the progress of the synthetic work, or
develop a new potential orexin receptor antagonist based on published structures of
antagonists that were reported to have high binding affinities.

Since the orexin family was discovered in 1998, much research has been done to develop
orexin receptor agonists and antagonists as potential drugs to treat sleep disorder and
obesity. However, this thesis presents another promising application of orexin receptor
agonists and antagonists in the molecular imaging area. Hopefully, the imaging agents
based on orexin agonists or antagonists can be developed successfully in the future and
will play a role in the early detection of colon cancer to increase the survival rate of
cancer patients.
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Appendix

HPLC and ESI-MS Spectra of Fluorescein-Ahx-Orexin A (15-33) (1)
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HPLC and ESI-MS Spectra of Fluorescein-Ahx-Orexin B (6-28) (3)
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'H-NMR and l3C-NMR Spectra of [2-(2-Amino-ethoxy)-ethoxy]-acetic acid (24)
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'H-NMR and 13C-NMR Spectra of 2-(2-Nitro-phenyl)-[l,3]dioxolane (53)
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'H-NMR and l3C-NMR Spectra of 2-Dibutoxymethyl-phenylamine (55)
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